Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults (Cochrane Review)

How we can help you
To learn more about Update Software and how we can provide solutions for your data management and web & CD publication needs visit our home page.

Useful resources
The Reproductive Health Library: the best evidence in sexual and reproductive health.
Evidence-based Health Care Workbook and CD-ROM

New abstracts this issue

Search abstracts

Alphabetical list of abstracts

Abstracts by Review Group

Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults (Cochrane Review)
Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto T, Walker SA

ABSTRACT

Background: Zidovudine (AZT) monotherapy was the first antiretroviral drug to be tested widely. Subsequent trials in asymptomatic or early symptomatic HIV infection indicated short-term delays in disease progression with AZT, but not improved survival.

Full article: The full article is available on Wiley InterScience at http://www.thecochranelibrary.com
Resources: WHO Reproductive Health Library, La Biblioteca Cochrane Plus, Renal Health Library, Malaria in Pregnancy Library
PubMed: Find related PubMed articles here [DarbyshireJ] [FoulkesM] [PetoR] [DuncanW] [BabikerA] [CollinsR] [HughesM] [PetoT] [WalkerSA]
Google Scholar: Find related Google Scholar articles here [DarbyshireJ] [FoulkesM] [PetoR] [DuncanW] [BabikerA] [CollinsR] [HughesM] [PetoT] [WalkerSA]